Follow-up studies of ovarian cancer patients indicated that those with high PABPC3 expression had a higher mortality rate post-treatment compared to patients with low expression, further supporting the role of PABPC3 in drug sensitivity. The gene discussed is PABPC3; the disease is ovarian cancer.